Clinical trials
Cutis Laxa trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
154 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 11 |
| 2012 | 6 |
| 2014 | 3 |
| 2015 | 6 |
| 2016 | 5 |
| 2017 | 2 |
| 2018 | 7 |
| 2019 | 9 |
| 2020 | 14 |
| 2021 | 7 |
| 2022 | 15 |
| 2023 | 20 |
| 2024 | 10 |
| 2025 | 17 |
| 2026 | 15 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 92 |
| Unknown status | 16 |
| Not yet recruiting | 14 |
| Recruiting | 14 |
| Terminated | 7 |
| Active, not recruiting | 6 |
| Enrolling by invitation | 3 |
| Withdrawn | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ulthera, Inc | 21 |
| Sofwave Medical LTD | 12 |
| Goldman, Butterwick, Fitzpatrick and Groff | 9 |
| BTL Industries Ltd. | 5 |
| Cynosure, Inc. | 5 |
| Apyx Medical | 4 |
| Candela Corporation | 4 |
| Cytrellis Biosystems, Inc. | 4 |
| FA Corporation | 3 |
| Lumenis Be Ltd. | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cutis Laxa | 154 |
| Blepharoptosis | 7 |
| Cicatrix | 7 |
| Striae Distensae | 5 |
| Weight Loss | 5 |
| Cellulite | 4 |
| Facies | 3 |
| Skin Diseases | 3 |
| Albinism | 2 |
| Alopecia | 2 |
Trials
Showing 1 to 25 of 154. Each trial links to its page on Pharma Observatory.
54 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.